Regulation mechanism of miR-494-3p on endometrial receptivity in mice via PI3K/AKT/mTOR pathway

被引:10
|
作者
Yuan, Lan [1 ]
Feng, Fen [2 ]
Mao, Zhu [3 ]
Huang, Jin-Zhu [3 ]
Liu, Yi [1 ]
Li, Yu-Lin [1 ]
Jiang, Rong-Xing [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Reprod & Women Children Hosp, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Sch Nursing, Chengdu, Sichuan, Peoples R China
关键词
Endometrial receptivity; miR-494-3p; PI3K/AKT/mTOR pathway; Leukemia inhibitory factor; EXPRESSION; GROWTH; ANGIOGENESIS; HORMONE; WINDOW; WOMEN;
D O I
10.4149/gpb_2021021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Successful implantation requires endometrial receptivity. To investigate the mechanisms of miR-494-3p on endometrial receptivity GnRHa's superovulation scheme was designed to reduce endometrial receptivity, and the pregnant mice were injected with miR-494-3p antagomir. The regulatory role of miR-494-3p was identified by RT-qPCR, uterine blastocyst count, scanning electron microscopy, hematoxylin-eosin (HE) staining, and Western blot. Results indicated that miR-494-3p antagomir increased uterine blastocysts numbers, promoted the pinocytosis expressions, and increased endometrial thickness. Besides, miR-494-3p antagomir significantly increased leukemia inhibitory factor (LIF), Ang-2 and VEGF protein expressions, and up-regulated p-AKT/AKT and p-mTOR/mTOR protein ratios in endometrium. Luciferase assay confirmed that LIF was a potential target of miR-494-3p. Subsequently, human endometrial epithelial cells (hEECs) were transfected with miR-494-3p inhibitor and PI3K inhibitor (LY294002). The role of miR-494-3p was identified by RT-qPCR, CCK-8 assay, transwell assay and flow cytometry. Results indicated that miR-494-3p inhibitor significantly increased proliferation and invasion, and significantly inhibited apoptosis in hEECs, while LY294002 reversed its biological function. Overall, these results suggested that miR-494-3p is the key regulator of endometrial receptivity in mice, regulating this complex process through the PI3K/AKT/TOR pathway. Understanding the role of miR-494-3p in endometrial receptivity is of great significance for exploring new targets for the diagnosis and treatment of early pregnancy failure, and improving the success rates of artificial reproduction.
引用
收藏
页码:351 / 363
页数:13
相关论文
共 50 条
  • [41] Targeting the mTOR/AKT/PI3K pathway in paediatric malignancies
    Pearson, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S74 - S74
  • [42] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [43] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [44] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [45] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [46] PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
    Lisi, Lucia
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2161 - 2163
  • [47] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [48] PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
    Zhang, Zixuan
    Wang, Mengzhao
    ONCOLOGY LETTERS, 2017, 14 (02) : 1373 - 1378
  • [49] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [50] RETRACTION: TJZYF Improves Endometrial Receptivity through Regulating VEGF and PI3K/AKT Signaling Pathway
    You, F.
    Du, X.
    Zhang, T.
    Wang, Y.
    Lv, Y.
    Zeng, L.
    BIOMED RESEARCH INTERNATIONAL, 2023, 2023